Key result
Maintenance therapy with ADV or alternating ACM-ADV resulted in similar median survival compared to ACM alone (13, 10, and 12 months, respectively), but with significantly worse toxicity.
Why the study?
Does maintenance therapy with ADV or alternating ACM-ADV improve survival or response duration compared to ACM alone in patients with metastatic sarcomas?
RCT (n=232)
Does maintenance therapy with ADV or alternating ACM-ADV improve survival or response duration compared to ACM alone in patients with metastatic sarcomas?
In patients with metastatic sarcomas, maintenance therapy with ADV or alternating ACM-ADV did not improve survival compared to ACM alone and was associated with worse toxicity.
No takes yet. Share an insight, caveat, or question.
Maintenance therapy should be omitted in metastatic sarcomas; confirms no role for these regimens and directs future trials elsewhere.
Presant et al. (1981) conducted an RCT in Metastatic sarcomas (n=232). ADV or alternating ACM-ADV vs. ACM was evaluated on Median survival. Maintenance therapy with ADV or alternating ACM-ADV resulted in similar median survival compared to ACM alone (13, 10, and 12 months, respectively), but with significantly worse toxicity.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: